"World's Most Complete Market Research Reports Repository"

Global Chronic Urticaria Or Hives Drug Market Research Report 2011-2023

Summary
The global Chronic Urticaria Or Hives Drug market will reach xxx Million USD in 2018 with CAGR xx% 2018-2023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.
Based on products type, the report describes major products type share of regional market. Products mentioned as follows:
GDC-0853
GSK-2646264
BF-Derm-1
Bilastine
Others
Leading vendors in the market are included based on profile, business performance etc. Vendors mentioned as follows:
AstraZeneca Plc
Biofrontera AG
ELORAC, Inc.
Faes Farma, SA
Genentech, Inc.
GlaxoSmithKline Plc
J Uriach Y Compania, S.A.
Mabtech Limited
Merck & Co., Inc.
Mycenax Biotech Inc.
Novartis AG
Panacea Biotec Limited
Based on Application, the report describes major application share of regional market. Application mentioned as follows:
Clinic
Hospital
Others
Based on region, the report describes major regions market by products and application. Regions mentioned as follows:
Asia-Pacific
North America
Europe
South America
Middle East & Africa

Table of Contents
1 Market Overview
1.1 Objectives of Research
1.1.1 Definition
1.1.2 Specifications
1.2 Market Segment
1.2.1 by Type
1.2.1.1 GDC-0853
1.2.1.2 GSK-2646264
1.2.1.3 BF-Derm-1
1.2.1.4 Bilastine
1.2.1.5 Others
1.2.2 by Application
1.2.2.1 Clinic
1.2.2.2 Hospital
1.2.2.3 Others
1.2.3 by Regions
2 Industry Chain
2.1 Industry Chain Structure
2.2 Upstream
2.3 Market
2.3.1 SWOT
2.3.2 Dynamics
3 Environmental Analysis
3.1 Policy
3.2 Economic
3.3 Technology
3.4 Market Entry
4 Market Segmentation by Type
4.1 Market Size
4.1.1 GDC-0853 Market, 2011-2016
4.1.2 GSK-2646264 Market, 2011-2016
4.1.3 BF-Derm-1 Market, 2011-2016
4.1.4 Bilastine Market, 2011-2016
4.1.5 Others Market, 2011-2016
4.2 Market Forecast
4.2.1 GDC-0853 Market Forecast, 2017-2022
4.2.2 GSK-2646264 Market Forecast, 2017-2022
4.2.3 BF-Derm-1 Market Forecast, 2017-2022
4.2.4 Bilastine Market Forecast, 2017-2022
4.2.5 Others Market Forecast, 2017-2022
5 Market Segmentation by Application
5.1 Market Size
5.1.1 Clinic Market, 2011-2016
5.1.2 Hospital Market, 2011-2016
5.1.3 Others Market, 2011-2016
5.2 Market Forecast
5.2.1 Clinic Market Forecast, 2017-2022
5.2.2 Hospital Market Forecast, 2017-2022
5.2.3 Others Market Forecast, 2017-2022
6 Market Segmentation by Region
6.1 Market Size
6.1.1 Asia-Pacific
6.1.1.1 Asia-Pacific Market, 2011-2016
6.1.1.2 Asia-Pacific Market by Type
6.1.1.3 Asia-Pacific Market by Application
6.1.2 North America
6.1.2.1 North America Market, 2011-2016
6.1.2.2 North America Market by Type
6.1.2.3 North America Market by Application
6.1.3 Europe
6.1.3.1 Europe Market, 2011-2016
6.1.3.2 Europe Market by Type
6.1.3.3 Europe Market by Application
6.1.4 South America
6.1.4.1 South America Market, 2011-2016
6.1.4.2 South America Market by Type
6.1.4.3 South America Market by Application
6.1.5 Middle East & Africa
6.1.5.1 Middle East & Africa Market, 2011-2016
6.1.5.2 Middle East & Africa Market by Type
6.1.5.3 Middle East & Africa Market by Application
6.2 Market Forecast
6.2.1 Asia-Pacific Market Forecast, 2017-2022
6.2.2 North America Market Forecast, 2017-2022
6.2.3 Europe Market Forecast, 2017-2022
6.2.4 South America Market Forecast, 2017-2022
6.2.5 Middle East & Africa Market Forecast, 2017-2022
7 Market Competitive
7.1 Global Market by Vendors
7.2 Market Concentration
7.3 Price & Factors
7.4 Marketing Channel
8 Major Vendors
8.1 AstraZeneca Plc
8.1.2 Profile
8.1.2 Business Performance (Sales Revenue, Cost, Gross Margin)
8.2 Biofrontera AG
8.2.1 Profile
8.2.2 Business Performance (Sales Revenue, Cost, Gross Margin)
8.3 ELORAC, Inc.
8.3.1 Profile
8.3.2 Business Performance (Sales Revenue, Cost, Gross Margin)
8.4 Faes Farma, SA
8.4.1 Profile
8.4.2 Business Performance (Sales Revenue, Cost, Gross Margin)
8.5 Genentech, Inc.
8.5.1 Profile
8.5.2 Business Performance (Sales Revenue, Cost, Gross Margin)
8.6 GlaxoSmithKline Plc
8.6.1 Profile
8.6.2 Business Performance (Sales Revenue, Cost, Gross Margin)
8.7 J Uriach Y Compania, S.A.
8.7.1 Profile
8.7.2 Business Performance (Sales Revenue, Cost, Gross Margin)
8.8 Mabtech Limited
8.8.1 Profile
8.8.2 Business Performance (Sales Revenue, Cost, Gross Margin)
8.9 Merck & Co., Inc.
8.9.1 Profile
8.9.2 Business Performance (Sales Revenue, Cost, Gross Margin)
8.10 Mycenax Biotech Inc.
8.10.1 Profile
8.10.2 Business Performance (Sales Revenue, Cost, Gross Margin)
8.11 Novartis AG
8.12 Panacea Biotec Limited
9 Conclusion

Table Product Specifications of Chronic Urticaria Or Hives Drug
Table Products Segment of Chronic Urticaria Or Hives Drug
Table GDC-0853 Overview
Table GSK-2646264 Overview
Table BF-Derm-1 Overview
Table Bilastine Overview
Table Others Overview
Table Global Chronic Urticaria Or Hives Drug Market by Type, 2011-2022 (USD Million)
Table Application Segment of Chronic Urticaria Or Hives Drug
Table Clinic Overview
Table Hospital Overview
Table Others Overview
Table Global Chronic Urticaria Or Hives Drug Market by Application, 2011-2022 (USD Million)
Table Global Chronic Urticaria Or Hives Drug Market by Region, 2011-2022 (USD Million)
Table Cost of Chronic Urticaria Or Hives Drug
Table Market Dynamics
Table Policy of Chronic Urticaria Or Hives Drug
Table GDP of Major Countries
Table GDC-0853 CAGR by Revenue and Volume, 2011-2016
Table GSK-2646264 CAGR by Revenue and Volume, 2011-2016
Table BF-Derm-1 CAGR by Revenue and Volume, 2011-2016
Table Bilastine CAGR by Revenue and Volume, 2011-2016
Table Others CAGR by Revenue and Volume, 2011-2016
Table GDC-0853 CAGR by Revenue and Volume, 2012-2022
Table GSK-2646264 CAGR by Revenue and Volume, 2012-2022
Table BF-Derm-1 CAGR by Revenue and Volume, 2012-2022
Table Bilastine CAGR by Revenue and Volume, 2012-2022
Table Others CAGR by Revenue and Volume, 2012-2022
Table Clinic CAGR by Revenue and Volume, 2011-2016
Table Hospital CAGR by Revenue and Volume, 2011-2016
Table Others CAGR by Revenue and Volume, 2011-2016

Choose License Type